Introduction {#Sec1}
============

Germline mutations in the *BRCA1* (MIM 113705) tumor suppressor gene confer an increased lifetime risk of breast and ovarian cancer. The absolute risk of cancer by the age of 70 years conferred by *BRCA1* mutations in female carriers is reported to be between 60 and 71 % for breast cancer and between 39 and 59 % for ovarian cancer \[[@CR1]--[@CR4]\]. Mutational screening has identified a large number of pathogenic *BRCA1* mutations in women with a family history of breast and/or ovarian cancer. Unfortunately, a substantial proportion of the sequence alterations identified during routine genetic testing are in-frame deletions/insertions, missense, silent, and intronic variants of uncertain clinical significance (VUS). A number of 1273 *BRCA1* VUS's have been reported by the ENIGMA (Evidence-Based Network for the Interpretation of Germline Mutant Alleles) consortium (up until September 2010) \[[@CR5]\]. Of these, the majority are missense variants, constituting a number of 781 unique variants. The identification of a VUS is associated with a complicated cancer risk assessment, genetic counseling, and clinical management of the patients and their families. Because most VUS occur at very low population frequencies, direct epidemiological measures, such as association studies, are often not adequately powerful to identify the variants associated with cancer predisposition \[[@CR6]\]. A promising approach is to add functional studies to characterize the biological effect of the variants and thereby provide clinicians with a better framework for counseling and treatment. It has been shown that a large portion of *BRCA1* variants induce splicing defects \[[@CR7]\]. Ideally, RNA from a patient should be examined by RT-PCR analysis to establish if a variant has an effect on splicing. However, in many cases, RNA is not available from the patient. Alternatively, the sequence variant can be examined by mini-gene splicing analysis, which has been shown to be a valid method for investigating the impact of an alteration on the splicing pattern \[[@CR8], [@CR9]\]. Here, we report the functional characterization of 14 *BRCA1* variants using in silico splicing analysis and a validated mini-gene splicing assay \[[@CR10]\]. All 14 variants were located in close proximity to splice donor/acceptor sites in the highly conserved BRCT domain and had previously been investigated by protein folding, phosphopeptide-binding, and cell-based transcriptional assays \[[@CR11]\]. The BRCT domain plays a critical role in tumor suppression and is considered to be one of two regions to contain the vast majority of cancer-associated mutations \[[@CR12]--[@CR16]\]. In summary, our study classified nine *BRCA1* variants as pathogenic as these variants affect mRNA splicing leading to out-of-frame exon skipping or the use of cryptic splice sites resulting in truncated transcripts, while five *BRCA1* variants were shown to have no effect on splicing.

Materials and methods {#Sec2}
=====================

Variant nomenclature {#Sec3}
--------------------

All missense variants were selected from the Breast Cancer Information Core (BIC) database \[[@CR17]\] and the literature \[[@CR11]\] based on the close proximity to the splice acceptor and splice donor sites. The *BRCA1* variants are numbered according to the guidelines from the Human Genome Variation Society (<http://www.hgvs.org/mutnomen>) using NCBI Reference Sequence NG_005905.2.

*In silico* analysis {#Sec4}
--------------------

The following five splice site prediction programs were used to predict the effect of variants on the efficiency of splicing: Splice Site Finder (<http://www.interactive-biosoftware.com>); GeneSplicer (<http://www.cbcb.umd.edu/software/GeneSplicer>); Splice Site Prediction by Neural Network (<http://www.fruitfly.org/seq_tools/splice.html>); MaxEntScan (<http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html>); and Human Splicing Finder (<http://www.umd.be/HSF/>). The analysis was performed by the integrated software Alamut version 2.4 (<http://www.interactive-biosoftware.com>) using default settings in all predictions. A variation of more than 10 % in at least two algorithms was considered as having an effect on splicing \[[@CR9]\].

Mini-gene splicing assay {#Sec5}
------------------------

Wild-type *BRCA1* exons were cloned into the pSPL3 vector (Fig. [1](#Fig1){ref-type="fig"}) and single nucleotide substitutions were introduced by mutagenesis performed using Finnzymes' Phusion High-Fidelity polymerase according to the accompanying instructions. Wild-type and mutant constructs were transfected in duplicate into COS-7 cells as recently described \[[@CR10]\]. Cells were harvested after 48 h and total RNA was extracted using Trizol reagent (Invitrogen). cDNA was synthesized using 1 µg of total RNA, M-MuLV reverse transcriptase polymerase (New England Biolabs), and 20 µM of nucleotide oligo(dT)~15~ primer. cDNA was amplified with Phusion DNA polymerase using the primers dUSD2 (5′-TCTGAGTCACCTGGACAACC-3′) and dUSA4 (5′-ATCTCAGTGGTATTTGTGAGC-3′). PCR products were separated by electrophoresis on a 1 % agarose gel containing ethidium bromide and quantified using Image Lab 2.0 software (Bio-Rad) (Fig. [2](#Fig2){ref-type="fig"}). Each DNA band was gel purified using GE Healthcare's Illustra GFX PCR DNA and Gel Band Purification Kit and sequenced with the dUSD2 and dUSA4 primers.Fig. 1Overview of *BRCA1* constructs. The different exons were cloned into the pSPL3 vector including a minimum of 250 bp intronic sequence. The exon--intron boundary sequence is shown and the mutated nucleotide is marked in bold for each *BRCA1* construct. *BRCA1* constructs covering: **a** exon 16, **b** exon 17, **c** exon 19, **d** exon 21, **e** exon 22, and **f** exon 23. IVS: intervening sequence, SA: splice acceptor site, SD: splice donor site, bp: basepairFig. 2Mini-gene splicing analysis of *BRCA1* variants. COS-7 cells were transfected with wild-type or mutant vectors in duplicate. Total RNA was isolated, RT-PCR analysis was performed, and PCR products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. Gel band intensities were quantified (Quant.) using the Image Lab 2.0 software. The sizes of the DNA marker (M) are indicated to the left. All PCR products were verified by Sanger sequencing. **a** The *BRCA1* c.4985T\>C/p.Phe1662Ser variant generated a strong 488-bp band corresponding to wild-type exon 16 (unaltered splicing) as well as a weak 177-bp band lacking exon 16 also present in the wild-type. **b** The *BRCA1* c.4987A\>T/p.Met1663Leu, c.4988T\>A/p.Met1663Lys, c.5072C\>T/p.Thr1691Ile, c.5074G\>C/p.Asp1692His, c.5074G\>A/p.Asp1692Asn, and c.5074G\>T/p.Asp1692Tyr variants all resulted in one strong band of 177 bp lacking exon 17. Moreover, c.4988T\>A/p.Met1663Lys and c.5072C\>T/p.Thr1691Ile also revealed a very weak wild-type band including exon 17, while c.5074G\>A/p.Asp1692Asn, c.5074G\>C/p.Asp1692His, and c.5074G\>T/p.Asp1692Tyr also generated a weak band comprising of 418 bp containing 153 bp of intron 17. The c.5072C\>A/p.Thr1691Lys variant had no major effect on splicing compared to the wild-type exon 17 (unaltered splicing). **c** The *BRCA1* c.5153G\>C/p.Trp1718Ser and c.5154G\>T/p.Trp1718Cys alterations both generated a 218-bp PCR product corresponding to wild-type exon 19 (unaltered splicing). **d** The *BRCA1* c.5332G\>A/p.Asp1778Asn and c.5332G\>T/p.Asp1778Tyr variants both resulted in one strong band of 177 bp lacking exon 21. **e** The *BRCA1* c.5333A\>G/p.Asp1778Gly variant produced a 251-bp product corresponding to wild-type exon 22 (unaltered splicing). **f** The *BRCA1* c.5408G\>C/p.Gly1803Ala variant resulted in one strong band of 177 bp lacking exon 23

Results {#Sec6}
=======

Previous studies have shown that a large portion of *BRCA1* variants induce splicing defects \[[@CR7]\]. In the present study, 14 *BRCA1* variants located near splice acceptor or donor sites in the conserved BRCT domain were examined using in silico splicing analysis and a validated mini-gene splicing assay \[[@CR7], [@CR10]\] (Table [1](#Tab1){ref-type="table"}). The in silico splicing analysis was performed using five different splice site prediction programs which predict changes in splice site strength. The applicable threshold was a variation between the wild-type and the variant score of more than 10 % in at least two different algorithms \[[@CR9]\]. According to this criterion, 10 *BRCA1* variants (c.4987A\>T/p.Met1663Leu, c.4988T\>A/p.Met1663Lys, c.5072C\>T/p.Thr1691Ile, c.5074G\>C/p.Asp1692His, c.5074G\>A/p.Asp1692Asn, c.5074G\>T/p.Asp1692Tyr, c.5153G\>C/p.Trp1718Ser, c.5332G\>A/p.Asp1778Asn, c.5332G\>T/p.Asp1778Tyr, and c.5408G\>C/p.Gly1803Ala) (Table [1](#Tab1){ref-type="table"}) were suggested to weaken the splice site strength, whereas the remaining four variants (c.4985T\>C/p.Phe1662Ser, c.5072C\>A/p.Thr1691Lys, c.5154G\>T/p.Trp1718Cys, and c.5333A\>G/p.Asp1778Gly) were not.Table 1Splicing prediction analysis of 14 *BRCA1* missense variantsExonNT change (HGVS)Protein changeSpliceSiteFinder\
(0--100)MaxEntScan\
(0--12)NNSplice\
(0--1)Gene splicer\
(0--15)Human splicing finder\
(0--100)Effect observed in\
mini-gene assayRNA change (HGVS)5-Tier splicing\
classification\*Classification based on Lee et al.\*\*Combined classification based on\* and\*\*16c.4985T\>Cp.Phe1662SerSD: 70.38/NI (−100 %)SD: 5.91/7.00 (+18.4 %)SD: 0.66/0.81 (+22.7 %)SD: NI/1.89 (+100 %)SD: 81.24/81.24 (0 %)Noner.\[=\]Class 2No effectClass 217c.4987A\>Tp.Met1663LeuSA: 84.55/82.21 (−2.8 %)SA: 6.69/5.26 (−21.4 %)SA: 0.61/NI (−100 %)SA: 1.36/NI (−100 %)SA: 87.03/85.86 (−1.3 %)Skipping of exon 17r.\[4987_5074del\]Class 5Low effectClass 517c.4988T\>Ap.Met1663LysSA: 84.55/84.55 (0 %)SA: 6.69/4.81 (−28.1 %)SA: 0.61/NI (−100 %)SA: 1.36/NI (−100 %)SA: 87.03/86.26 (−0.9 %)Skipping of exon 17 and minor wild-type transcript (7 %)r.\[4987_5074del\]Class 5No effectClass 517c.5072C\>Ap.Thr1691LysSD: 71.90/71.59 (−0.4 %)SD: 7.48/7.64 (2.1 %)SD: 0.92/0.89 (−3.3 %)SD: NI/NISD: 76.86/75.90 (−1.2 %)Noner.\[=\]Class 2Strong effectClass 517c.5072C\>Tp.Thr1691IleSD: 71.90/NI (−100 %)SD: 7.48/4.69 (−37.3 %)SD: 0.92/0.56 (−39.1 %)SD: NI/NISD: 76.86/74.87 (−2.6 %)Skipping of exon 17 and minor wild-type transcript (17.5 %)r.\[4987_5074del\]Class 5Strong effectClass 517c.5074G\>Cp.Asp1692HisSD: 71.90/NI (−100 %)SD: 7.48/NI (−100 %)SD: 0.92/NI (−100 %)SD: NI/NISD: 76.86/65.84 (−14.3 %)Skipping of exon 17 and in-frame retention of 153 bp of intron 17r.\[4987_5074del, 5074_5075ins5074 + 1\_ 5074 + 153\]Class 5Uncertain effectClass 517c.5074G\>Ap.Asp1692AsnSD: 71.90/NI (−100 %)SD: 7.48/NI (−100 %)SD: 0.92/NI (−100 %)SD: NI/NI (−100 %)SD: 76.86/66.28 (−13.8 %)Skipping of exon 17 and in-frame retention of 153 bp of intron 17r.\[4987_5074del, 5074_5075ins5074 + 1\_ 5074 + 153\]Class 5Low effectClass 517c.5074G\>Tp.Asp1692TyrSD: 71.90/NI (−100 %)SD: 7.48/NI (−100 %)SD: 0.92/NI (−100 %)SD: NI/NISD: 76.86/65.99 (−14.1 %)Skipping of exon 17 and in-frame retention of 153 bp of intron 17r.\[4987_5074del, 5074_5075ins5074 + 1\_ 5074 + 153\]Class 5Uncertain effectClass 519c.5153G\>Cp.Trp1718SerSA: 81.95/76.19 (−7.0 %)SA: 8.78/7.02 (−20.0 %)SA: 0.96/0.77 (−19.8 %)SA: 5.11/4.02 (−21.3 %)SA: 83.79/79.63 (−5.0 %)Noner.\[=\]Class 2Strong effectClass 519c.5154G\>Tp.Trp1718CysSA: 81.95/81.95 (0 %)SA: 8.78/9.95 (13.3 %)SA: 0.96/0.98 (2.1 %)SA: 5.11/7.12 (39.3 %)SA: 83.79/84.39 (0.7 %)Noner.\[=\]Class 2Strong effectClass 521c.5332G\>Ap.Asp1778AsnSD: 94.67/82.54 (−12.8 %)SD: 10.77/7.61 (−29.3 %)SD: 1.00/0.96 (−4.0 %)SD: 8.13/3.90 (−52.0 %)SD: 97.66/87.09 (−10.8 %)Skipping of exon 21r.\[5278_5332del\]Class 5No effectClass 521c.5332G\>Tp.Asp1778TyrSD: 94.67/82.06 (−13.3 %)SD: 10.77/5.58 (−48.2 %)SD: 1.00/0.94 (−6 %)SD: 8.13/3.54 (−52.0 %)SD: 97.66/86.80 (−11.1 %)Skipping of exon 21r.\[5278_5332del\]Class 5No effectClass 522c.5333A\>Gp.Asp1778GlySA: 73.01/76.92 (5.4 %)SA: 8.67/9.73 (12.2 %)SA: 0.67/0.89 (32.8 %)SA: 6.38/7.51 (17.7 %)SA: 80.46/83.59 (3.9 %)Noner.\[=\]Class 2No effectClass 223c.5408G\>Cp.Gly1803AlaSA: 76.41/76.41 (0 %)SA: 4.86/4.29 (−11.7 %)SA: NI/NISA: 2.48/1.83 (−26.2 %)SA: 83.39/83.14 (−0.3 %)Skipping of exon 23r.\[5407_5467del\]Class 5Uncertain effectClass 5The thresholds represent score predicted for wild-type sequence/score predicted for mutated sequence. The scores indicate the values for splice donor (SD) or splice acceptor (SA) sites, respectively. Changes relative to wild-type sequences are indicated in  %*NI* not identified\* The 5-Tier splicing classification is based on Spurdle et al. \[[@CR34]\] and Walker et al. \[[@CR35]\]\*\* Classification of the variants based on functional studies on protein level (Lee et al. \[[@CR11]\])

The functional effects of all 14 *BRCA1* variants on mRNA splicing were subsequently examined by mini-gene splicing assays. Each construct was transfected into COS-7 cells in duplicate and cells were harvested. mRNA was then purified and analyzed by RT-PCR. Finally, PCR products were visualized by ethidium bromide staining of 1 % agarose gels (Fig. [2](#Fig2){ref-type="fig"}a--f) and sequenced. In line with the in silico splicing results, nine *BRCA1* variants (c.4987A\>T/p.Met1663Leu, c.4988T\>A/p.Met1663Lys, c.5072C\>T/p.Thr1691Ile, c.5074G\>C/p.Asp1692His, c.5074G\>A/p.Asp1692Asn, c.5074G\>T/p.Asp1692Tyr, c.5332G\>A/p.Asp1778Asn, c.5332G\>T/p.Asp1778Tyr, and c.5408G\>C/p.Gly1803Ala) revealed the presence of alternative gel bands compared to the corresponding wild-types. The wild-type *BRCA1* exon 17 construct revealed the presence of one major transcript comprising the expected 265 bp containing exon 17 and a very weak band of 177 bp lacking exon 17. The c.4987A\>T/p.Met1663Leu, c.4988T\>A/p.Met1663Lys, c.5072C\>T/p.Thr1691Ile, c.5074G\>C/p.Asp1692His, c.5074G\>A/p.Asp1692Asn, and c.5074G\>T/p.Asp1692Tyr variants all yielded one major band of 177 bp lacking exon 17 (Fig. [2](#Fig2){ref-type="fig"}b). In addition to the 177 bp band, the c.5074G\>A/p.Asp1692Asn, c.5074G\>C/p.Asp1692His, and c.5074G\>T/p.Asp1692Tyr alterations generated a weaker band comprising of 418 bp containing 153 bp of intron 17 by the usage of a cryptic splice donor site. Furthermore, besides the 177 bp band, the c.4988T\>A/p.Met1663Lys and c.5072C\>T/p.Thr1691Ile variants presented with a very weak wild-type band at 265 bp constituting 7 % and 17.5 % of the total amount of transcript, respectively (Fig. [2](#Fig2){ref-type="fig"}b). Wild-type *BRCA1* exon 21 generated one transcript at the expected 232 bp, while the c.5332G\>A/p.Asp1778Asn and c.5332G\>T/p.Asp1778Tyr variants resulted in one strong band of 177 bp excluding exon 21 (Fig. [2](#Fig2){ref-type="fig"}d). Finally, wild-type *BRCA1* exon 23 revealed a single transcript at the expected size of 238 bp, while c.5408G\>C/p.Gly1803Ala resulted in one strong band of 177 bp lacking exon 23 (Fig. [2](#Fig2){ref-type="fig"}f). In contrast to the in silico splicing data, c.5153G\>C/p.Trp1718Ser (Fig. [2](#Fig2){ref-type="fig"}c) did not show any splicing abnormality since both the wild-type *BRCA1* exon 19 and the c.5153G\>C/p.Trp1718Ser variant generated one strong band at the expected size of 218 bp containing exon 19. In accordance with the in silico splicing results, the remaining four variants (c.4985T\>C/p.Phe1662Ser, c.5072C\>A/p.Thr1691Lys, c.5154G\>T/p.Trp1718Cys, and c.5333A\>G/p.Asp1778Gly) (Fig. [2](#Fig2){ref-type="fig"}a--d) showed no difference in size or intensity of the bands between wild-type and mutant constructs.

Discussion {#Sec7}
==========

Genetic screening for pathogenic mutations in breast and ovarian cancer genes *BRCA1* and *BRCA2* is common practice for individuals from high-risk families. However, the test often results in identification of a VUS, leading to impeded cancer risk estimation and clinical management \[[@CR18]\]. Therefore, it is important to classify all identified *BRCA1*/*BRCA2* sequence variants \[[@CR19]\]. It has previously been established that all variation types in *BRCA1* can lead to splicing abnormalities \[[@CR7]\]. Hence, it is important to include investigations at the RNA level when classifying a variant.

In this study, we examined 14 *BRCA1* variants located in close proximity to the exon--intron boundary regarding their effect on mRNA splicing using in silico splicing analysis along with a validated mini-gene splicing assay \[[@CR10]\]. All variants are very rare in the general population, and only two of the variants (c.4985T\>C and c.5333A\>G) have been reported once in the ExAC database containing data from approximately 60,000 unrelated individuals with different population origin \[[@CR20]\].

Six variants (c.4987A\>T/p.Met1663Leu, c.4988T\>A/p.Met1663Lys, c.5072C\>T/p.Thr1691Ile, c.5074G\>C/p.Asp1692His, c.5074G\>A/p.Asp1692Asn, and c.5074G\>T/p.Asp1692Tyr) were shown to cause out-of-frame skipping of exon 17 (Fig. [2](#Fig2){ref-type="fig"}B), a result that was in agreement with the results predicted by in silico splicing analysis (Table [1](#Tab1){ref-type="table"}) \[[@CR11]\]. The c.4987A\>T/p.Met1663Leu, c.4988T\>A/p.Met1663Lys, and c.5072C\>T/p.Thr1691Ile variants are reported in the BIC database as VUS. Functional studies and in silico predictions have previously shown that the c.4987A\>T/p.Met1663Leu and c.4988T\>A/p.Met1663Lys missense variants had low or no functional effect on protein level \[[@CR11], [@CR21], [@CR22]\]. In contrast, functional and in silico studies showed that the c.5072C\>T/p.Thr1691Ile variant had a strong effect on protein function \[[@CR11], [@CR21]\].

The c.5074G\>C/p.Asp1692His, c.5074G\>A/p.Asp1692Asn, and c.5074G\>T/p.Asp1692Tyr missense variants are reported in the BIC database as variants of clinical importance. Studies on the protein level classified c.5074G\>C/p.Asp1692His as having an uncertain effect on protein function \[[@CR11]\], while in silico and functional studies showed that the c.5074G\>A/p.Asp1692Asn variant, previously reported as an Icelandic founder mutation \[[@CR23]\], had low or no impact on the protein level \[[@CR11], [@CR22], [@CR24]\]. The c.5074G\>T/p.Asp1692Tyr variant has been predicted to have an effect on the protein level by in silico analysis \[[@CR21], [@CR22]\] as well as in one functional assay based on measurement of the thermodynamic stability of the BRCA1 BRCT domain \[[@CR22]\], while other functional assays based on proteolysis, phosphopeptide-binding, and transcription assays were inconclusive \[[@CR11]\]. In this study, the c.5074G\>A/p.Asp1692Asn, c.5074G\>C/p.Asp1692His, and c.5074G\>T/p.Asp1692Tyr variants were shown to induce skipping of exon 17 as well as usage of a cryptic splice donor site located at c.5074 + 153 in intron 17. The use of this cryptic splice site has previously been reported for the c.5074G\>C/p.Asp1692His variant using lymphoblastoid cell lines (LCLs) or patient blood samples \[[@CR25], [@CR26]\].

The two variants, c.5332G\>A/p.Asp1778Asn and c.5332G\>T/p.Asp1778Tyr, located in exon 21 near the exon--intron boundary also resulted in out-of-frame exon skipping (Fig. [2](#Fig2){ref-type="fig"}d) and hence are classified as pathogenic. The c.5332G\>A/p.Asp1778Asn variant is reported once in the BIC database as a VUS, whereas the c.5332G\>T/p.Asp1778Tyr variant has not previously been reported. Our data regarding the c.5332G\>A/p.Asp1778Asn variant are in agreement with recent splicing data using RNA from patient blood samples \[[@CR27]\]. Both the c.5332G\>A/p.Asp1778Asn variant and the c.5332G\>T/p.Asp1778Tyr variant have previously been shown to have no effect on protein level using functional assays and in silico analysis \[[@CR11], [@CR12], [@CR21], [@CR22]\].

The final variant that showed aberrant splicing using the mini-gene splicing assay was c.5408G\>C/p.Gly1803Ala (Fig. [2](#Fig2){ref-type="fig"}f). This variant caused out-of-frame skipping of exon 23 of *BRCA1*. The c.5408G\>C/p.Gly1803Ala variant has been reported three times in the BIC database as a VUS and functional studies as well as in silico analysis showed that the variant had an uncertain or no effect on the protein level \[[@CR11], [@CR21]\].

The following five variants---c.4985T\>C/p.Phe1662Ser, c.5072C\>A/p.Thr1691Lys, c.5153G\>C/p.Trp1718Ser, c.5154G\>T/p.Trp1718Cys, and c.5333A\>G/p.Asp1778Gly---did not show any splicing abnormality when investigated by the mini-gene splicing assay (Fig. [2](#Fig2){ref-type="fig"}a--c, e). This result was in accordance with the in silico splicing prediction except for the c.5153G\>C/p.Trp1718Ser variant which was suggested to affect splicing by all the programs used (Table [1](#Tab1){ref-type="table"}). All five variants are reported in the BIC database as VUS. Three variants (c.5072C\>A/p.Thr1691Lys, c.5153G\>C/p.Trp1718Ser, and c.5154G\>T/p.Trp1718Cys) have been shown to have a strong functional effect on the protein level \[[@CR11]\]. In addition, structural examination of c.5072C\>A/p.Thr1691Lys showed that the alteration significantly disturbed the surface of the binding pocket interacting with the BACH1 phosphorylated peptide \[[@CR28]--[@CR30]\]. Both c.4985T\>C/p.Phe1662Ser and c.5333A\>G/p.Asp1778Gly missense variants have been reported to have a low functional effect on the protein level \[[@CR11]\]. In addition, the c.4985T\>C/p.Phe1662Ser variant has previously been classified as a variant of no clinical significance based on in silico analysis \[[@CR31]\]. Finally, the c.5333A\>G/p.Asp1778Gly variant has previously been tested for its effect on mRNA splicing using LCLs or patient blood samples \[[@CR25], [@CR32]\], and the results are in agreement with the result shown in Fig. [2](#Fig2){ref-type="fig"}e.

The mini-gene assay used in this study has recently been validated and showed a 100 % concordance with results using patient blood samples \[[@CR10]\]. However, there are limitations using a mini-gene assay, since the assay examine the expression of an artificial transcript usually containing one exon and varying amounts of flanking intron sequences, compared to assessing the natural endogenous expression of *BRCA1* transcripts. The use of mini-gene constructs containing only one exon will moreover miss more complex changes (e.g. skipping of more exons). Finally, the COS-7 cell line used in the mini-gene assay may not fully reflect the splicing machinery used in breast tissue. However, since *BRCA1* alternative splicing is similar in breast tissue and blood samples \[[@CR33]\], and the use of COS-7 cells showed a 100 % concordance with results using patient blood samples \[[@CR10]\], we infer that the basal splicing machinery necessary for correct *BRCA1* splicing is present in COS-7 cells.

Another caveat is the finding that natural occurring *BRCA1* isoforms lacking exons 17, 21, and 23 exist \[[@CR33]\]. However, since other *BRCA1* variants inducing exon 17, 21, and 23 skipping are classified as pathogenic in the BIC database (c.4987-1G\>A, c.5074 + 1G\>T, c.5074 + 1G\>A, c.5074 + 2T\>C, c.5278-1G\>T, c.5332 + 1G\>A, c.5407-1G\>A, c.5407-2A\>T, c.5467 + 1G\>A, and c.5467 + 2T\>C), we classify *BRCA1* exon 17, 21, and 23 missense variants inducing skipping as pathogenic (class 5) even though minor amounts of naturally occurring transcripts lacking these exons exist.

In conclusion, using in silico splicing prediction and a validated mini-gene splicing assay, we classified nine *BRCA1* variants as pathogenic (c.4987A\>T/p.Met1663Leu, c.4988T\>A/p.Met1663Lys, c.5072C\>T/p.Thr1691Ile, c.5074G\>C/p.Asp1692His, c.5074G\>A/p.Asp1692Asn, c.5074G\>T/p.Asp1692Tyr, c.5332G\>A/p.Asp1778Asn, c.5332G\>T/p.Asp1778Tyr, and c.5408G\>C/p.Gly1803Ala), since the variants affected mRNA splicing leading to out-of-frame exon skipping or the use of cryptic splice sites resulting in truncated transcripts. All nine variants had previously been investigated at the protein level but only one of the variants (c.5072C\>T/p.Thr1691Ile) showed a strong functional effect \[[@CR11], [@CR21]\]. The remaining five *BRCA1* variants (c.4985T\>C/p.Phe1662Ser, c.5072C\>A/p.Thr1691Lys, c.5153G\>C/p.Trp1718Ser, c.5154G\>T/p.Trp1718Cys, and c.5333A\>G/p.Asp1778Gly) had no effect on splicing when examined by the mini-gene splicing assay. However, three of these variants (c.5072C\>A/p.Thr1691Lys, c.5153G\>C/p.Trp1718Ser, and c.5154G\>T/p.Trp1718Cys) had previously been shown to have a strong functional effect on the protein level \[[@CR11]\]. Our results clearly demonstrate the relevance of assessing missense variants for possible splicing defects before final classification. However, the splicing data should, when possibly, be combined with multifactorial likelihood analysis, based on co-segregation, family history, tumor pathology, and co-occurrence with a pathogenic *BRCA1* mutation to support the conclusions before the findings are used in the clinic.

We thank Stine Østergaard for technical assistance. This study was supported by the Familien Hede Nielsens Foundation.

Conflict of interest {#d30e1478}
====================

The authors declare no conflict of interest.
